Fast-Track Your Initial Clinical Use in China with the Hainan RWD/S Pilot Program

Fast-Track Your Initial Clinical Use in China with the Hainan RWD/S Pilot Program

  • Version
  • 27 Download
  • 0.00 KB File Size
  • 1 File Count
  • December 2, 2020 Create Date
  • April 8, 2021 Last Updated
  • Subscribe To Watch

Learn how the Hainan Real-World Data/Study (RWD/Study) pilot program can shave months off your timeline for initial clinical use of NMPA unapproved devices in a real-world setting. This initiative allows overseas medical devices, IVDs and drugs that have NOT been approved in China to be sold and used in real world clinical settings in Lecheng Hainan province and is particularly significant for overseas manufacturers with high-value and innovative devices that normally require clinical trials by China NMPA.

In this webcast you’ll receive guidance on how the program works, and the RWD/S in NMPA registration approval directly from Hainan officials. Tune in to learn if and how the program can accelerate your commercial sales and registration in China.


File
QbBHCzqYy9M